• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-14

  The reference study identifies CD44-mediated metabolic rewiring as a functional dependency of IDH-mutant leukemia, linking pentose phosphate pathway activity and NADPH production to sustained R-2HG synthesis. Its findings suggest that combining mutant IDH inhibition with CD44 blockade may address a metabolic vulnerability that is not fully captured by 2-HG suppression alone.

• FLOT1–FOSL2–EphA2 Signaling in Alzheimer’s Disease

  2026-09-14

  A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 regulatory axis that activates p38/MAPK signaling and promotes pro-inflammatory microglial polarization in an APP/PS1 model. FLOT1 silencing reduced neuroinflammatory responses and improved spatial memory, providing a mechanistic framework for connecting lipid-raft-associated regulation with cognitive decline in Alzheimer’s disease.

• Maternal IL-17A and Neonatal GBS Risk

  2026-09-13

  A prospective Moroccan mother–newborn study identifies reduced maternal IL-17A responses as a candidate marker of invasive Group B Streptococcus disease after vertical transmission. By combining maternal and cord-blood cytokine profiling with ex vivo TLR stimulation, the work connects immune-response phenotyping with neonatal risk stratification while highlighting important limits for clinical translation.

• MLKL Polymerization and Lysosomal Membrane Permeabilization

  2026-09-12

  The reference study identifies MLKL polymerization-induced lysosomal membrane permeabilization as a critical execution step in necroptosis, placing lysosomal cathepsin B release between necrosome activation and plasma membrane rupture. Its live-cell imaging, MLKL-domain perturbation, and cathepsin B loss-of-function experiments provide a framework for dissecting lysosomal enzyme inhibition in regulated cell death.

• Baricitinib (LY3009104): JAK1/2–STAT3

  2026-09-11

  Baricitinib, also known as LY3009104 and INCB028050, is an orally bioavailable, ATP-competitive JAK1/JAK2 inhibitor. Its low-nanomolar biochemical potency and suppression of STAT3 phosphorylation support research on IL-6, IL-23, immune signaling, and preclinical arthritis models.

• Verbascoside: PKC/NF-κB Signaling Guide

  2026-09-11

  Verbascoside is a PKC/NF-κB inhibitor used to study inflammatory signaling and osteoclastogenesis. Product-dossier data report an approximately 4.8 μM cellular IC50 in RANKL-treated RAW264.7 cells and bone marrow macrophages, while direct activity in TMJ neuroinflammation remains unestablished.

• Baricitinib: Reliable JAK1/2 Assay Design

  2026-09-10

  This scenario-based guide shows how Baricitinib (LY3009104, INCB028050), SKU A4141, can support reproducible JAK-STAT pathway experiments, from DMSO stock preparation to orthogonal viability and signaling readouts. It connects quantitative product data with practical controls, assay interpretation, and translational limitations.

• Vitamin D/VDR Signaling in Endometrial Decidualization

  2026-09-10

  This study identifies vitamin D receptor (VDR) signaling as a positive regulator of human endometrial stromal-cell decidualization. Its experiments connect VDR activity with CYP19-dependent estrogen production, providing a mechanistic framework for understanding how vitamin D may influence endometrial receptivity and infertility-related biology.

• Vincristine Sulfate: Mechanism & Research Use

  2026-09-09

  Vincristine sulfate is a tubulin polymerization inhibitor that disrupts microtubule dynamics and suppresses proliferating cancer cells. This guide separates supplier-reported biochemical and xenograft benchmarks from established oncology uses and practical research controls.

• GSK621 AMPK Agonist: Workflow & Applications

  2026-09-09

  GSK621 is a potent AMPK agonist for connecting energy-sensing biology with acute myeloid leukemia research and immunometabolic assays. This practical guide covers formulation, pathway validation, AML phenotyping, macrophage applications, comparison with A-769662, and troubleshooting.

• ER–Ca2+–Calpain Control of Starvation Cell Fate

  2026-09-08

  A 2026 study in Bombyx mori identifies ER calcium dysregulation and calpain activation as a temporal switch from protective autophagy to apoptosis during prolonged starvation. Its use of 2-APB links IP3R-dependent calcium signaling to ATG5 cleavage and caspase-3 activation, while also highlighting the need for pharmacological and genetic controls.

• Cell Counting Kit-8 for Prostate Cancer Studies

  2026-09-08

  Use Cell Counting Kit-8 to quantify viable prostate cancer cells while preserving a simple, scalable workflow for proliferation and drug-response studies. This guide connects WST-8 readouts with apoptosis, invasion, and pathway-focused experiments inspired by SLAMF8 research.

• PDHA1 Succinylation and α-KGA Immune Escape

  2026-09-07

  A 2025 Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic control point in cholangiocarcinoma. The modification increases alpha-ketoglutarate accumulation, activates OXGR1–MAPK signaling in macrophages, suppresses MHC-II antigen presentation, and provides a preclinical rationale for combining succinylation-directed intervention with gemcitabine and cisplatin.

• Dual HER2–VEGFR2 Targeting in TNBC Metastasis

  2026-09-07

  The reference study investigates lapatinib plus Telatinib (BAY 57-9352) in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its central contribution is a phenotype-focused preclinical framework linking dual tyrosine kinase inhibition with reduced proliferation, invadopodia formation, and 2D angiogenic tube formation, while leaving target engagement, formal drug synergy, and in vivo efficacy unresolved.

• Maternal Deltamethrin, Ferroptosis, and Memory

  2026-09-05

  A 2025 study shows that maternal deltamethrin exposure impairs hippocampal learning and memory in male offspring through a p53-associated SLC7A11/GPX4 ferroptosis pathway. Its integration of behavioral, histological, biochemical, calcium-signaling, and pharmacological evidence offers a useful framework for studying developmental neurotoxicity.

8125 records 1/542 page Next 12345 下5页 Last page